Aterovax SA, a company developing innovative products for atherosclerosis, announced at the AHA scientific sessions (November 14-18, 2009, Orlando, USA) data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein. sPLA2 is a family of pro-inflammatory enzymes liked to the formation and destabilization of atherosclerotic plaques. Aterovax's sPLA2 activity test was used in 3778 patients in the PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition) trial and the results were presented at the American Heart Association's annual scientific sessions... Aterovax's Press Releases -
About Aterovax
Aterovax is an emerging biopharmaceutical company focused on the development of its own portfolio of innovative products for a better diagnostic, prevention and treatment of atherosclerosis. This pathological condition underlies several important adverse vascular events including coronary artery disease, stroke and peripheral arterial disease, and is responsible for most of the cardiovascular morbidity and mortality in the developed and under development countries today... About Aterovax -
